Interestingly, ERBB2 mutations were detected in four gastric adenocarcinomas, raising the possibility of testing a HER-2 inhibitor such as trastuzumab in gastric cancer patients selected based on this genetic criterion [8]. This evidence concerns the gene ERBB2 and gastric adenocarcinoma.